SCHEMBL544334

SCHEMBL544334

Cn1cc2c(C=O)c(Cl)ccc2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MAOA P21397 2/20 0.36
MAOB P27338 2/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
ATM Q13315 1/20 0.35
SMN1; SMN2 Q16637 5/20 0.33
RAB9A P51151 3/20 0.33
MAPT P10636 2/20 0.33
POLB P06746 1/20 0.33
DUSP3 P51452 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
HTT P42858 1/20 0.32
NOD2 Q9HC29 1/20 0.32
BRD4 O60885 2/20 0.32
CREBBP Q92793 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL544133 0.80 ERN1 (0.36) ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL543357 0.80 MAOA (0.36) ALDH1A1MEN1KMT2AMAOAMAOB
SCHEMBL21631725 0.79 ADORA2A (0.38) ALDH1A1TDP1MEN1KMT2AADORA2A
SCHEMBL2779086 0.79 L3MBTL1 (0.44) ALDH1A1MEN1KMT2AMAOAMAOB
SCHEMBL544049 0.77 RAB9A (0.36) ALDH1A1TDP1MEN1KMT2AMAOA
SCHEMBL543225 0.75 MTNR1A (0.36) ALDH1A1MEN1KMT2AMAOAMAOB
SCHEMBL543226 0.75 MTNR1A (0.36) ALDH1A1MEN1KMT2AMAOAMAOB
SCHEMBL31751052 0.74 MAOA (0.36) ALDH1A1MAOAMAOBADORA2AADORA1
SCHEMBL10257517 0.73 CA12 (0.40) MAOBADORA2AADORA1RAB9AMAPT
SCHEMBL544070 0.72 MEN1 (0.41) ALDH1A1TDP1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2141150-B1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2013-12-11 EP disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
CN-101687810-A Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL 2010-03-31 CN disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 EP disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF MTNR1A, MTNR1B, XDH ALDH1A1 1431/4885TDP1 4627/4885MEN1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.